CASE REPORT We present a patient with serious contracted bladder and bilateral grade V vesicoureteral reflux which developed after intravesical MitomycinC treatment. The 78yearsold male patient had a history of transurethral bladder tumor and prostate resection at the same session in another center, because of a solitary, papillary tumour with a diameter of 20 mm near the left ureteral orifice and an enlarged prostate. Before the operation intravenous urography was done, showed normal bladder capacity (figure 1). The histology revealed transitional cell carcinoma (T1, G1) and benign prostatic hyperplasia. Intravesically 20 mg MitomycinC was given weekly for the first six weeks, then monthly for 10 months. During the treatment he developed increasing frequency and urge incontinence, but the treatment was not interrupted. Two years after the end of instillation the patient presented to our department with right flank pain, frequency and urge incontinence. Serum levels of creatinine and urea were 228 μmol/L and 11.3 mmol/L, respectively. Urine culture, including culture for tuberculosis, was negative. His renal ultrasound showed bilateral hydronephrosis, and thin renal cortex. Cystogram revealed contracted bladder and bilateral grade V vesicoureteral reflux (figure 2). Cystoscopy showed golfhole ureteral orifices and low capacity (50 ml) of the bladder. There were no sign of tumour recurrence. Due to comorbidity of the patient (hypertension, ischemic heart disease) reconstructive surgery could not be performed; therefore percutaneous suprapubic cystostomy was placed. One year after suprapubic cystostomy placement, the patient was very well, he had no symptoms and his serum level of creatinine stabilized at about 150 μmol/L. DISCUSSION MitomycinC, doxorubicin and epirubicin are the most frequently used intravesical chemotherapy to prevent recurrence of superficial bladder cancer after transurethral resection. These drugs can be used for single, immediate, postoperative instillation or for adjuvant repeat instillations. The efficacy of these drugs are similar [1, 2]. Side effects of intravesical chemotherapy (cystitis, bladder irritation) are usually moderate and localized to the bladder. However, rarely it can cause severe, even fatal, complications, especially after immediate postoperative instillation when there is a bladder wall perforation [3]. MitomycinC is considered to be a safe intravesical chemotherapeutic drug, but rarely it can cause contracted bladder, which can require urinary diversion [4]. The cause of contracted bladder in the present case was most likely chemocystitis caused by intravesical MitomycinC therapy; we were able to exclude other common cause of contracted bladder (tuberculosis, schistosomiasis, interstitial cystitis, irradiation cystitis). Perhaps, longterm (1yearlong) treatment and the absence of treatment interruption, even though the patient’s symptoms facilitated this serious adverse effect. CLINICAL IMAGES OPEN ACCESS